Many patients receiving intravitreal injections for retinal disease require ongoing treatment for several years. Vabysmo is an attractive treatment approved by the FDA in 2022 which may require fewer visits per year. Vabysmo is a bispecific antibody for both VEGF-A and angiopoietin 2 (Ang-2). Ang-2 is a cytokine associated with vascular destabilization and microvascular inflammation. This dual blockade of VEGF and Ang-2 may prove to make faricimab more attractive for treatment of wet age-related macular degeneration and diabetic macular edema. The dual blockage seems to allow for longer treatment intervals. Trials have shown that vabysmo given every three to four months may be as effective as available agents given every one to two months for the treatment of diabetic macular edema and wet age-related macular degeneration.